13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001618205
Total reported value
$213.8M
$213.8M
68 檔
29.2%
In Q4 2024, Birchview Capital, LP's U.S. equity holdings reached a combined market value of $213.8M, distributed across 68 disclosed stock positions.
In Q4 2024, Birchview Capital, LP displayed an active expansion posture, initiating 10 new positions and adding to 12 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 31.53% | -2.56% | -0.15% | |
| 2 | ✓ | Biodesix Inc | Stock-Other | 7.14% | +0.65% | +0.70% | |
| 3 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 5.05% | -0.15% | -15.48% | |
| 4 | ELUT | Elutia Inc | Stock-Other | 3.73% | -0.02% | -7.25% | |
| 5 | PRTA | Prothena Corporation plc | Stock-Other | 3.43% | -0.42% | +45.33% | |
| 6 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 3.36% | +0.10% | — | |
| 7 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 3.03% | +1.25% | — | |
| 8 | UTHR | United Therapeutics CORP | Stock-Healthcare | 2.87% | -0.38% | — | |
| 9 | AXGN | Axogen Inc | Stock-Other | 2.64% | — | — | |
| 10 | DCGO | Docgo Inc | Stock-Other | 2.64% | — | +48.36% | |
| 11 | QDELUSD | Quidelortho CORP | Stock-Other | 2.45% | -0.04% | — | |
| 12 | PHR | Phreesia Inc | Stock-Other | 2.35% | -0.07% | EXIT | |
| 13 | TVTX | Travere Therapeutics Inc | Stock-Other | 2.10% | +0.28% | — | |
| 14 | MASI* | Masimo CORP | Stock-Other | 2.06% | — | — | |
| 15 | HROW | Harrow Inc | Stock-Other | 1.99% | — | — | |
| 16 | STOK | Stoke Therapeutics Inc | Stock-Other | 1.88% | -1.16% | — | |
| 17 | OVV | Ovintiv Inc | Stock-Energy | 1.72% | -0.98% | — | |
| 18 | CSTL | Castle Biosciences Inc | Stock-Other | 1.69% | -0.04% | +34.48% | |
| 19 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.51% | -0.09% | — | |
| 20 | EQT | Eqt CORP | Stock-Energy | 1.30% | -0.39% | — | |
| 21 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 1.19% | -0.13% | -3.12% | |
| 22 | ALKS | Alkermes plc | Stock-Healthcare | 1.17% | +0.22% | — | |
| 23 | TMCI | Treace Medical Concepts Inc | Stock-Other | 0.98% | — | +136.06% | |
| 24 | NVCR | NovoCure Limited | Stock-Healthcare | 0.75% | -1.26% | EXIT | |
| 25 | TXG | 10x Genomics Inc-class A | Stock-Other | 0.58% | — | +66.67% | |
| 26 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.55% | -0.74% | EXIT | |
| 27 | XNCR | Xencor Inc | Stock-Other | 0.49% | — | +111.38% | |
| 28 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.48% | — | — | |
| 29 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.46% | -0.65% | EXIT | |
| 30 | ATEC | Alphatec Holdings Inc | Stock-Other | 0.43% | — | -70.71% | |
| 31 | CADL | Candel Therapeutics Inc | Stock-Other | 0.42% | +0.06% | — | |
| 32 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.40% | — | — | |
| 33 | INBX | Inhibrx Biosciences Inc | Stock-Other | 0.40% | — | — | |
| 34 | HALO | Halozyme Therapeutics Inc | Stock-Healthcare | 0.39% | +0.85% | — | |
| 35 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.38% | +0.07% | — | |
| 36 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 0.36% | -0.32% | EXIT | |
| 37 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.35% | — | +40.00% | |
| 38 | OMGBP | Outset Medical Inc | Stock-Other | 0.33% | -0.22% | EXIT | |
| 39 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.32% | -0.11% | — | |
| 40 | ✓ | Accelerate Diagnostics Inc | Stock-Other | 0.32% | — | — | |
| 41 | TELA | Tela Bio Inc | Stock-Other | 0.31% | — | — | |
| 42 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 0.29% | — | — | |
| 43 | QURE | uniQure N.V. | Stock-Other | 0.29% | +0.15% | — | |
| 44 | LUNG | Pulmonx CORP | Stock-Other | 0.28% | -0.06% | — | |
| 45 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.28% | — | — | |
| 46 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.28% | +0.11% | — | |
| 47 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.24% | — | — | |
| 48 | ATRA | Atara Biotherapeutics Inc | Stock-Other | 0.24% | — | — | |
| 49 | ARVN | Arvinas Inc | Stock-Other | 0.23% | — | — | |
| 50 | KPTIEUR | Karyopharm Therapeutics Inc | Stock-Other | 0.23% | -0.07% | -10.64% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DCGO | Docgo Inc | +1.2% | +48.36% | Add |
| 2 | BMY | Bristol-myers Squibb Co | +0.8% | -0.15% | Trim |
| 3 | TMCI | Treace Medical Concepts Inc | +0.6% | +136.06% | Add |
| 4 | RARE | Ultragenyx Pharmaceutical In | +0.6% | NEW | New buy |
| 5 | NVCR | NovoCure Limited | +0.5% | +55.00% | Add |
| 6 | CADL | Candel Therapeutics Inc | +0.4% | NEW | New buy |
| 7 | PRTA | Prothena Corporation plc | +0.4% | +45.33% | Add |
| 8 | NBIX | Neurocrine Biosciences Inc | +0.3% | — | Unchanged |
| 9 | OMGBP | Outset Medical Inc | +0.3% | +3587.66% | Add |
| 10 | TVTX | Travere Therapeutics Inc | +0.3% | — | Unchanged |
| 11 | TELA | Tela Bio Inc | +0.3% | NEW | New buy |
| 12 | MASI* | Masimo CORP | +0.3% | — | Unchanged |
| 13 | XNCR | Xencor Inc | +0.3% | +111.38% | Add |
| 14 | LUNG | Pulmonx CORP | +0.3% | NEW | New buy |
| 15 | SRRK | Scholar Rock Holding CORP | +0.3% | NEW | New buy |
| 16 | CSTL | Castle Biosciences Inc | +0.3% | +34.48% | Add |
| 17 | AXGN | Axogen Inc | +0.3% | — | Unchanged |
| 18 | ATRA | Atara Biotherapeutics Inc | +0.2% | NEW | New buy |
| 19 | EQT | Eqt CORP | +0.2% | — | Unchanged |
| 20 | QURE | uniQure N.V. | +0.2% | — | Unchanged |
| 21 | MLTX | Moonlake Immunotherapeutics | +0.2% | NEW | New buy |
| 22 | WVE | Wave Life Sciences Ltd. | +0.1% | — | Unchanged |
| 23 | ZBIO | Zenas Biopharma Inc | +0.1% | NEW | New buy |
| 24 | TECL | Dire Dai Tec Bull 3x Etf-usd | +0.1% | NEW | New buy |
| 25 | PHR | Phreesia Inc | +0.1% | — | Unchanged |
| 26 | NPCE | Neuropace Inc | +0.1% | NEW | New buy |
| 27 | SRPT | Sarepta Therapeutics Inc | +0.1% | +40.00% | Add |
| 28 | CORT | Corcept Therapeutics Inc | +0.1% | — | Unchanged |
| 29 | IFRX | InflaRx N.V. | 0% | — | Unchanged |
| 30 | APLSUSD | Apellis Pharmaceuticals Inc | 0% | — | Unchanged |
| 31 | SWTXUSD | Springworks Therapeutics Inc | 0% | — | Unchanged |
| 32 | LQDA | Liquidia CORP | 0% | — | Unchanged |
| 33 | FENG | Phoenix New Media Limited | — | — | Unchanged |
| 34 | VTYXUSD | Ventyx Biosciences Inc | — | — | Unchanged |
| 35 | OVV | Ovintiv Inc | 0% | — | Unchanged |
| 36 | TXG | 10x Genomics Inc-class A | 0% | +66.67% | Add |
| 37 | ZNTL | Zentalis Pharmaceuticals Inc | 0% | +6.25% | Add |
| 38 | TSVT* | 2seventy Bio Inc | 0% | — | Unchanged |
| 39 | GOSS | Gossamer Bio Inc | 0% | — | Unchanged |
| 40 | BCRX | Biocryst Pharmaceuticals Inc | 0% | — | Unchanged |
| 41 | XENE | Xenon Pharmaceuticals Inc | 0% | — | Unchanged |
| 42 | ALMS | Alumis Inc | 0% | — | Unchanged |
| 43 | AXSM | Axsome Therapeutics Inc | 0% | — | Unchanged |
| 44 | 2655787D | Blueprint Medicines CORP | 0% | — | Unchanged |
| 45 | CABA | Cabaletta Bio Inc | 0% | EXIT | Sold out |
| 46 | ALKS | Alkermes plc | 0% | — | Unchanged |
| 47 | INBX | Inhibrx Biosciences Inc | 0% | — | Unchanged |
| 48 | AM6 | Amicus Therapeutics Inc | -0.1% | — | Unchanged |
| 49 | CYTK | Cytokinetics Inc | -0.1% | — | Unchanged |
| 50 | CGEM | Cullinan Therapeutics Inc | -0.1% | — | Unchanged |
According to official SEC Form 13F filings, Birchview Capital, LP reported a total U.S. public equity portfolio value of $213.8M across 68 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BMY, BIODESIX INC, ACAD) accounted for 29.2% of total reported equity market value during Q4 2024.
Top New Position Initiated
RARE
市值: $673.1K
Top Position Liquidated / Trimmed
PGNY
前期市值: $368.7K
During Q4 2024, Birchview Capital, LP's top holdings by market value included BMY (31.5%)、BIODESIX INC (7.1%)、ACAD (5.0%). The largest single position, BMY, represented 31.5% of total portfolio value.
In Q4 2024, Birchview Capital, LP made 33 total portfolio adjustments, initiating 10 new buys, adding to 12 positions, trimming 8 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.